- Home
- ACXP vs MYNZ Comparison
ACXP vs MYNZ Comparison
Compare ACXP & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- MYNZ
- Stock Information
- Founded
- ACXP 2017
- MYNZ 2021
- Country
- ACXP United States
- MYNZ Germany
- Employees
- ACXP N/A
- MYNZ N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- ACXP Health Care
- MYNZ Health Care
- Exchange
- ACXP Nasdaq
- MYNZ Nasdaq
- Market Cap
- ACXP 8.4M
- MYNZ 8.0M
- IPO Year
- ACXP 2021
- MYNZ 2021
- Fundamental
- Price
- ACXP $0.35
- MYNZ $2.08
- Analyst Decision
- ACXP Strong Buy
- MYNZ Buy
- Analyst Count
- ACXP 2
- MYNZ 2
- Target Price
- ACXP $10.00
- MYNZ $14.00
- AVG Volume (30 Days)
- ACXP 235.0K
- MYNZ 93.5K
- Earning Date
- ACXP 05-13-2025
- MYNZ 06-17-2025
- Dividend Yield
- ACXP N/A
- MYNZ N/A
- EPS Growth
- ACXP N/A
- MYNZ N/A
- EPS
- ACXP N/A
- MYNZ N/A
- Revenue
- ACXP N/A
- MYNZ $893,991.00
- Revenue This Year
- ACXP N/A
- MYNZ $26.06
- Revenue Next Year
- ACXP N/A
- MYNZ $4.97
- P/E Ratio
- ACXP N/A
- MYNZ N/A
- Revenue Growth
- ACXP N/A
- MYNZ N/A
- 52 Week Low
- ACXP $0.30
- MYNZ $1.92
- 52 Week High
- ACXP $3.33
- MYNZ $34.00
- Technical
- Relative Strength Index (RSI)
- ACXP 37.87
- MYNZ 38.07
- Support Level
- ACXP $0.34
- MYNZ $1.93
- Resistance Level
- ACXP $0.36
- MYNZ $2.10
- Average True Range (ATR)
- ACXP 0.02
- MYNZ 0.16
- MACD
- ACXP -0.00
- MYNZ 0.04
- Stochastic Oscillator
- ACXP 5.19
- MYNZ 30.39
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.